LT2013109A - Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai - Google Patents
Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijaiInfo
- Publication number
- LT2013109A LT2013109A LT2013109A LT2013109A LT2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A LT 2013109 A LT2013109 A LT 2013109A
- Authority
- LT
- Lithuania
- Prior art keywords
- infections
- atherosclerosis
- cardivascular
- prevention
- antisense oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Šis išradimas yra iš mikrobiologijos srities. Išradimas siūlo priešprasminius oligonukleotidus (PO), farmacines kompozicijas, apimančias PO, būdą slopinti bakterinių bioplėvelių atsiradimą ir augimą žmogaus kardiovaskuliniuose audiniuose ir žmogaus kraujo terpėje, siekiant aterosklerozės ir kardiovaskulinių infekcijų prevencijos ir gydymo.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LT2013109A LT6214B (lt) | 2013-10-07 | 2013-10-07 | Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai |
PCT/IB2014/065084 WO2015052630A1 (en) | 2013-10-07 | 2014-10-06 | Antisense oligonucleotides for prevention of atherosclerosis and cardiovascular infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LT2013109A LT6214B (lt) | 2013-10-07 | 2013-10-07 | Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai |
Publications (2)
Publication Number | Publication Date |
---|---|
LT2013109A true LT2013109A (lt) | 2015-04-27 |
LT6214B LT6214B (lt) | 2015-08-25 |
Family
ID=51871111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT2013109A LT6214B (lt) | 2013-10-07 | 2013-10-07 | Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai |
Country Status (2)
Country | Link |
---|---|
LT (1) | LT6214B (lt) |
WO (1) | WO2015052630A1 (lt) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US6228982B1 (en) | 1992-05-22 | 2001-05-08 | Benget Norden | Double-stranded peptide nucleic acids |
DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
US5766855A (en) | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
GB9211979D0 (en) | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
GB2284209A (en) | 1993-11-25 | 1995-05-31 | Ole Buchardt | Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template |
US5705333A (en) | 1994-08-05 | 1998-01-06 | The Regents Of The University Of California | Peptide-based nucleic acid mimics(PENAMS) |
AU3584897A (en) * | 1996-06-21 | 1998-01-07 | Virginia Commonwealth University | Vaccine to prevent streptococcal endocarditis |
US6107470A (en) | 1997-05-29 | 2000-08-22 | Nielsen; Peter E. | Histidine-containing peptide nucleic acids |
NZ556114A (en) * | 2004-12-06 | 2010-02-26 | Kane Biotech Inc | Peptides capable of inhibiting Streptococcus mutans genetic competence and biofilm formation |
WO2014033314A1 (en) * | 2012-09-03 | 2014-03-06 | Uab Bioseka | Antisense oligonucleotide targeting bacterial glucosyltransferases |
-
2013
- 2013-10-07 LT LT2013109A patent/LT6214B/lt not_active IP Right Cessation
-
2014
- 2014-10-06 WO PCT/IB2014/065084 patent/WO2015052630A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015052630A1 (en) | 2015-04-16 |
LT6214B (lt) | 2015-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017502141A1 (en) | Compounds and their methods of use | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
WO2014022739A3 (en) | Modified rnai agents | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
MX355632B (es) | Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres. | |
MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
PH12014502513A1 (en) | Nampt inhibitors | |
MX2014013752A (es) | Inhibidores de nampt. | |
GB2496342B (en) | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
WO2013120022A3 (en) | Treatment of hypoglycemia | |
MX348397B (es) | Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico. | |
EP3594346A4 (en) | ANTISENSE OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA | |
MX2015001648A (es) | Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos. | |
WO2011103028A3 (en) | Compositions and methods for inhibiting mmset | |
WO2011116351A3 (en) | Methods and compositions for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Patent application published |
Effective date: 20150427 |
|
FG9A | Patent granted |
Effective date: 20150825 |
|
MM9A | Lapsed patents |
Effective date: 20161007 |